Therefore, ACS treatment in the HDP group showed significantly decreased protective effects against the development of PVL, short-term composite adverse outcomes, CP, and DQ < 85 at 3 years of age compared with the non-HDP group. Here, CP is linked to periventricular leukomalacia.